Navigation Links
Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
Date:9/24/2007

PITTSBURGH, Sept. 24 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") today announced the initiation of a Phase 1 clinical trial of KNS-760704, a small molecule therapy in development for the treatment of amyotrophic lateral sclerosis (ALS).

(Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO )

This randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers is being closely followed by a multiple ascending dose study in healthy subjects. Both studies are designed to evaluate the safety, tolerability and pharmacokinetics of KNS-760704 in human subjects.

"The initiation of Phase 1 represents a significant milestone in Knopp's efforts to develop a safe and effective therapy for a serious unmet medical need," said Michael Bozik, M.D., president and chief executive officer of Knopp. "We look forward to completing these safety studies and moving rapidly to advance the compound into initial clinical trials in ALS patients."

About KNS-760704

KNS-760704 is an orally administered small molecule in clinical development by Knopp for the treatment of amyotrophic lateral sclerosis (ALS). The drug is an optical enantiomer of a selective, high affinity dopamine agonist marketed in other neurological indications. Both KNS-760704 and the marketed agonist demonstrate neuroprotective properties independent of dopamine receptor activity, but KNS-760704 exhibits greatly reduced dopamine receptor affinity. This makes it possible to clinically evaluate the potential neuroprotective activity of KNS-760704 over a broad dose range.

About ALS

Amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease, is a rapid, universally fatal neurodegenerative disorder characterized by progressive muscle weakness and wasting. ALS affects adults in the prime of life and creates a substantial burden for caregivers. U.
'/>"/>

SOURCE Knopp Neurosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 /PRNewswire-iReach/ -- Phoenix Houses of California ... organization, is hosting its tenth annual "Triumph For Teens" ... 6, 2013.  More than 300 people are expected to ... residential treatment centers, family therapy, and prevention programs of ... have positive influences on the health and welfare of our ...
(Date:5/24/2013)... Corporation (NASDAQ: HSKA, "Heska" or the "Company"), a leading provider ... Robert Grieve , the Company,s chairman and ... executive vice president and chief financial officer, will present at ... May 30, 2013 in New York City ... Company,s presentation is scheduled to begin at 1:30 p.m. EDT. ...
(Date:5/24/2013)... 2013 In accordance with Rule 17.1 and Rule ... the United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty ... Corporation (NYSE: ELN). Background On 2 ... offer for the entire of the issued and to be ... Offer").  On 20 May 2013, Royalty Pharma ...
Breaking Medicine Technology:Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9
... , WESTWOOD, Mass., Dec. 7 CompuCyte Corporation, ... and the leading supplier of laser scanning cytometers, announced ... of imaging cytometers to include four-laser versions of the ... four excitation lasers chosen from a palette of 405, ...
... PARIS, December 7 , - ... the Clinical Relevance of Oralair(R) , ... III,clinical trial (VO53.06) to assess the long-term (sustained) effect and,disease ... immunotherapy tablet, Oralair(R). This study is the first ever,pivotal study ...
Cached Medicine Technology:CompuCyte Announces the Release of Four-Laser Imaging Cytometers 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5
(Date:5/24/2013)... 2013 myMEDholiday.com, a popular medical tourism ... in five important medical travel destinations in Asia, has ... to ensure a safe and successful trip for ... manual offers tips on cost-savings, how to find the ... and a wealth other essential advice. , A top-level ...
(Date:5/24/2013)... 2013 Range Kleen Mfg. strives to “TCOTC.” ... Customer, from the President's desk to the Shipping Dock.” We ... integrity, and having passion while creating excellence and quality being ... company to do the right thing and what better way ... affected by devastation. , Throughout the year Range Kleen donates ...
(Date:5/24/2013)... This week is National EMS Week, which recognizes ... the best emergency care and to improve health communications ... to educate the public that all can play a ... first link, and a very important one. According to ... cardiac arrest can triple a victim’s chance of survival. ...
(Date:5/24/2013)... 24 (HealthDay News) -- Patients hospitalized for heart failure ... admitted on Mondays or in the morning, a new ... are highest among heart failure patients admitted in January, ... are scheduled to present their findings Saturday in Portugal ... of the European Society of Cardiology. "The ...
(Date:5/24/2013)... 2013 KC and Monica Craichy, Founders of ... FreeRide836. Their oldest sons, Kyle and Austin Craichy, will be ... and several professional kiteboarders. , KC Craichy said he is ... miraculously come together such that virtually everyone who planned to ... 20 kite boarders will meet at Matheson Hammock Park and ...
Breaking Medicine News(10 mins):Health News:myMEDholiday.com Introduces International Patient Guide to Assist People Planning Treatment Abroad 2Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3
... ... entire chapter dedicated to this persistent, unpleasant side effect of general anesthesia -- postoperative ... anesthesia as a non-PONV technique in the latest Miller,s ,Anesthesia, top anesthesia textbook. ... Corona del Mar, ...
... , CAPE TOWN, South Africa, June 9 The ... growth over the next five years, driven by an ... procedures. However, price sensitivity and competition in the market ... to purchase imaging systems and the financial constraints faced ...
... 8 Brookdale Senior Living Inc. (NYSE: BKD ... disclosed public offering of 13,953,489 shares of common stock, at ... underwriters in the offering exercised in full their option to ... at the public offering price, resulting in net proceeds to ...
... , , Editorial note: Call (202) 303-5551 to speak with ... WASHINGTON, June 8 The upcoming transition ... on the disaster preparedness plans of many people who have relied ... disaster, and the American Red Cross urges you to update your ...
... Donor Mass , , WASHINGTON, June 8 ... ceremony to honor the 54 men and women who donated ... The yearly Donor Mass celebrated on Georgetown,s campus, was attended ... who chose to make this unique gift in order to ...
... especially strong among those in their 20s, study finds, , ... in colorectal cancer rates in the United States in the ... actually on the upswing among people younger than 50. , ... -- now running annually at 2.8 percent and 2.2 percent ...
Cached Medicine News:Health News:Anesthesia Can Make Patients Vomit After Cosmetic Surgery - World's Top Expert Says PK Anesthesia Is Better 2Health News:Anesthesia Can Make Patients Vomit After Cosmetic Surgery - World's Top Expert Says PK Anesthesia Is Better 3Health News:Frost & Sullivan: Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 2Health News:Frost & Sullivan: Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 3Health News:Frost & Sullivan: Replacement of Old Equipment Boosts Kenyan Medical Imaging Industry 4Health News:Brookdale Announces Completion of Follow-On Offering 2Health News:Brookdale Announces Completion of Follow-On Offering 3Health News:Brookdale Announces Completion of Follow-On Offering 4Health News:Brookdale Announces Completion of Follow-On Offering 5Health News:Digital TV Transition Coming Soon; Update Preparedness Plans 2Health News:Digital TV Transition Coming Soon; Update Preparedness Plans 3Health News:A Sacred Celebration: Georgetown School of Medicine Honors Donors 2Health News:Colorectal Cancer Rates Rising for Under 50 Set 2Health News:Colorectal Cancer Rates Rising for Under 50 Set 3
Inquire...
... a premium agarose used for isolating DNA ... produces clear sharp bands, with no smearing ... UltraClean Forensic Agarose is tested and certified ... activity and DNA contamination. Meets ...
... 1000 is specifically formulated for high resolution ... <1000 bp. This standard melting temperature agarose ... as 10 bp difference in size. ... gel structure for better handling and improved ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
Medicine Products: